Innate Pharma Stock Performance
| IPHA Stock | USD 1.78 0.02 1.14% |
The company retains a Market Volatility (i.e., Beta) of 0.46, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Innate Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Innate Pharma is expected to be smaller as well. At this point, Innate Pharma has a negative expected return of -0.0903%. Please make sure to check out Innate Pharma's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Innate Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Innate Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Innate Pharma Projected to Post Quarterly Earnings on Thursday | 11/06/2025 |
2 | Why Innate Pharma S.A. Depositary Receipt stock is a must watch in 2025 - Weekly Investment Report Free Growth Oriented Trading Recommendations - newser.com | 11/12/2025 |
3 | Innate Pharma S.A. Q3 2025 Earnings Call Transcript | 11/18/2025 |
4 | Innate Pharma details 2026 financial calendar with key reporting and AGM dates - Stock Titan | 12/10/2025 |
5 | Innate Pharma Updates Share Capital and Voting Rights as of December 31, 2025 - TipRanks | 01/07/2026 |
6 | Published on 2026-01-27 005240 - baoquankhu1.vn | 01/26/2026 |
| Begin Period Cash Flow | 70.6 M | |
| Total Cashflows From Investing Activities | 9.2 M |
Innate Pharma Relative Risk vs. Return Landscape
If you would invest 199.00 in Innate Pharma on October 30, 2025 and sell it today you would lose (21.00) from holding Innate Pharma or give up 10.55% of portfolio value over 90 days. Innate Pharma is currently does not generate positive expected returns and assumes 4.6429% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Innate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Innate Pharma Target Price Odds to finish over Current Price
The tendency of Innate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.78 | 90 days | 1.78 | about 71.61 |
Based on a normal probability distribution, the odds of Innate Pharma to move above the current price in 90 days from now is about 71.61 (This Innate Pharma probability density function shows the probability of Innate Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Innate Pharma has a beta of 0.46. This usually indicates as returns on the market go up, Innate Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Innate Pharma will be expected to be much smaller as well. Additionally Innate Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Innate Pharma Price Density |
| Price |
Predictive Modules for Innate Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Innate Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Innate Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Innate Pharma is not an exception. The market had few large corrections towards the Innate Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Innate Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Innate Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 0.46 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | -0.04 |
Innate Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innate Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innate Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma may become a speculative penny stock | |
| Innate Pharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 12.62 M. Net Loss for the year was (49.47 M) with loss before overhead, payroll, taxes, and interest of (30.79 M). | |
| Innate Pharma currently holds about 123.35 M in cash with (6.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54. | |
| Latest headline from news.google.com: Published on 2026-01-27 005240 - baoquankhu1.vn |
Innate Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innate Stock often depends not only on the future outlook of the current and potential Innate Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innate Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 81.1 M | |
| Cash And Short Term Investments | 80.8 M |
Innate Pharma Fundamentals Growth
Innate Stock prices reflect investors' perceptions of the future prospects and financial health of Innate Pharma, and Innate Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innate Stock performance.
| Return On Equity | -2.71 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (5.23) % | ||||
| Current Valuation | 127.32 M | ||||
| Shares Outstanding | 93.71 M | ||||
| Price To Book | 27.04 X | ||||
| Price To Sales | 13.20 X | ||||
| Revenue | 12.62 M | ||||
| Gross Profit | (30.79 M) | ||||
| EBITDA | (46.91 M) | ||||
| Net Income | (49.47 M) | ||||
| Cash And Equivalents | 123.35 M | ||||
| Cash Per Share | 1.54 X | ||||
| Total Debt | 31 M | ||||
| Debt To Equity | 0.37 % | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (6.9 M) | ||||
| Earnings Per Share | (0.65) X | ||||
| Market Capitalization | 166.8 M | ||||
| Total Asset | 111.06 M | ||||
| Retained Earnings | (386.36 M) | ||||
| Working Capital | 52.76 M | ||||
About Innate Pharma Performance
By analyzing Innate Pharma's fundamental ratios, stakeholders can gain valuable insights into Innate Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Innate Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innate Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 52.05 | 37.48 | |
| Return On Tangible Assets | (0.51) | (0.49) | |
| Return On Capital Employed | (0.59) | (0.56) | |
| Return On Assets | (0.51) | (0.49) | |
| Return On Equity | (6.44) | (6.12) |
Things to note about Innate Pharma performance evaluation
Checking the ongoing alerts about Innate Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Innate Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innate Pharma generated a negative expected return over the last 90 days | |
| Innate Pharma may become a speculative penny stock | |
| Innate Pharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 12.62 M. Net Loss for the year was (49.47 M) with loss before overhead, payroll, taxes, and interest of (30.79 M). | |
| Innate Pharma currently holds about 123.35 M in cash with (6.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.54. | |
| Latest headline from news.google.com: Published on 2026-01-27 005240 - baoquankhu1.vn |
- Analyzing Innate Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innate Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Innate Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innate Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innate Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innate Pharma's stock. These opinions can provide insight into Innate Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |